iPierian Garners $22,000,000 Series B Financing

  • Feed Type
  • Date
    7/8/2010
  • Company Name
    iPierian
  • Mailing Address
    951 Gateway Blvd South San Francisco, CA 94080
  • Company Description
    iPierian is a pioneering biopharmaceutical company that is taking the cutting-edge technologies of cellular reprogramming and directed differentiation to an entirely new level to harness the power of induced pluripotent stem cells to advance the understanding of human diseases and accelerate the discovery of more effective therapeutics for patients. iPierian has built one of the most qualified teams of stem cell scientists in the world, combining the expertise of the founding scientists of what was formerly iZumi Bio with internationally-renowned scientists from top institutions such as the Harvard Stem Cell Institute and University of California San Francisco among others. iPierian is the first company to apply cellular reprogramming and directed differentiation to cells that are derived from patients representing a broad spectrum of diseases.
  • Website
    http://www.ipierian.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $22,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    This financing will allow the company to drive its programs into the clinic, while securing pharmaceutical partnerships.
  • M&A Terms
  • Venture Investor
    Google Ventures
  • Venture Investor
    Mitsubishi Corporation
  • Venture Investor
    Atel Ventures, Inc.
  • Venture Investor
    MPM Capital
  • Venture Investor
    Highland Capital Partners
  • Venture Investor
    Kleiner Perkins Caufield & Byers

By posting a comment, you agree to our terms and conditions.